5364W-13 A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Ri

A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation (VENTURE-AF)

Type of Study
Heart & Vascular - Electrophysiology
Short Description

The objective of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist in adult subjects with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation, as measured by post-procedure major bleeding events

Status
Open
Principal Investigator
Darryl Wells, MD
Eligibility Notes

Subjects must be 18 years of age, or older, scheduled for his/her first catheter ablation procedure for NVAF, and have a documented history of paroxysmal (lasting <1 week) or persistent (lasting >1 week and <1 year or requiring pharmacological or electrical cardioversion) NVAF.

Contact Name
Elizabeth Vogt, PhD and Inger Rasmussen
Phone
206-320-3917
Alternate Phone
206-215-3989
Email
elizabeth.vogt@swedish.org
Alternate Email
inger.rasmussen@swedish.org